Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
News|Articles|November 6, 2026
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
Author(s)Monique O'Connell, PharmD, AAHIV
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Advertisement
Advertisement
GLP-1 receptor agonists (GLP-1 RAs) have rapidly become an important part of clinical practice. Initially approved for the treatment of type 2 diabetes, these agents are now widely used for obesity and have expanded into additional indications, including cardiovascular risk reduction, metabolic dysfunction-associated steatohepatitis (MASH), and obstructive sleep apnea. As use of medications such as semaglutide, tirzepatide, dulaglutide, and liraglutide continues to grow, specialty pharmacists are increasingly likely to encounter patients receiving these therapies during or around cancer treatment.
Related to this article
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Advertisement
Advertisement